Changes in Beneficial Ownership · 4
Zentalis Pharmaceuticals, Inc.
ZNTLNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1781813274.xml
Filing details
- Report period
- 2026-06-16
- Issuer
- Zentalis Pharmaceuticals, Inc.
- Issuer CIK
- 0001725160
- Trading symbol
- ZNTL
Reporting owner 1
- Name
- Walker Luke Nathaniel
- Reporting owner CIK
- 0001701440
- Relationship
- Director
- Address
- C/O ZENTALIS PHARMACEUTICALS, INC., 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-06-16 | A · Form 4 | 57,100[F1] | A | 0 | 201,384 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.↩ 1
Remarks
Exhibit 24 - Power of Attorney
Signature 1
- Signed
- James B. Bucher, attorney-in-fact for Luke Walker
- Date
- 2026-06-18
Filed exhibits
- EX-24.1 ↗zntlpowerofattorney-luke.htm
Company context
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.